- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | Biodesix, Inc.: Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs | 1 | GlobeNewswire (USA) | ||
| 04.06. | Biodesix auf der 45. jährlichen William Blair Growth Stock Konferenz: Fokus auf Lungengesundheit | 3 | Investing.com Deutsch | ||
| 30.05. | BIODESIX INC - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 22.05. | Biodesix, Inc.: Biodesix Announces New Data on the VeriStrat Test to be Presented at the 2025 ASCO Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 21.05. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 21.05. | Scotiabank cuts Biodesix stock target to $2, maintains outlook | 3 | Investing.com | ||
| 15.05. | Biodesix, Inc.: Biodesix Announces New Clinical and Economic Data for its Nodify Lung Tests at ISPOR and ATS | 119 | GlobeNewswire (Europe) | LOUISVILLE, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced that new data will be presented at the International Society for... ► Artikel lesen | |
| BIODESIX Aktie jetzt für 0€ handeln | |||||
| 15.05. | Biodesix Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 1 | Benzinga.com | ||
| 14.05. | Biodesix, Inc.: Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award | 1 | GlobeNewswire (USA) | ||
| 14.05. | Biodesix Analysts Lower Their Forecasts After Downbeat Q1 Results | 1 | Benzinga.com | ||
| 14.05. | Biodesix GAAP EPS of -$0.08 misses by $0.02, revenue of $18M misses by $3.23M | 3 | Seeking Alpha | ||
| 14.05. | Biodesix stock rating cut to Market Perform at William Blair | 5 | Investing.com | ||
| 14.05. | Canaccord cuts Biodesix stock target to $1.50, keeps buy rating | 1 | Investing.com | ||
| 14.05. | Biodesix revises 2025 revenue guidance to $80M-$85M amid sales force reconfiguration and primary care expansion | 1 | Seeking Alpha | ||
| 13.05. | BIODESIX INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 13.05. | Biodesix, Inc.: Biodesix Announces First Quarter 2025 Results and Highlights | 131 | GlobeNewswire (Europe) | Total Q1 2025 Revenue of $18.0 million, an increase of 21% over Q1 2024; Gross margins of 79.4% for Q1 2025; Q1 2025 Net loss improved by 18% compared to Q1 2024; Updated 2025 Revenue Guidance to... ► Artikel lesen | |
| 29.04. | Biodesix, Inc.: Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025 | 1 | GlobeNewswire (USA) | ||
| 23.04. | Biodesix, Inc.: Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types | 3 | GlobeNewswire (USA) | ||
| 17.04. | BIODESIX INC - 8-K, Current Report | 1 | SEC Filings | ||
| 04.03. | Biodesix, Inc. (BDSX): Among Penny Stocks with Insider Buying in 2025 | 1 | Insider Monkey |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PAION | 0,017 | -16,16 % | Paion Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| GUARDANT HEALTH | 38,160 | -1,27 % | Cathie Wood's ARK ETFs shift focus, buying NVIDIA and selling GUARDANT | ||
| QIAGEN | 42,730 | +2,82 % | QIAGEN N.V.: QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels | Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications... ► Artikel lesen | |
| EVOTEC | 6,358 | +2,05 % | Biotech-Hoffnung enttäuscht: Evotec kappt Umsatzprognose und die Aktie schmiert zweistellig ab | © Foto: Breuel-Bild/dpaEvotec hat die Umsatzprognose für das laufende Geschäftsjahr deutlich gesenkt. Das Hamburger Biotechunternehmen rechnet nun mit Konzernerlösen zwischen 760 und 800 Millionen Euro.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 28,010 | 0,00 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
| ARCELLX | 69,97 | +2,52 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 57,09 | +3,03 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies | The Breakthrough Therapy Designation (BTD) was granted based on the highly compelling results from the Phase 2 EMBOLD trial in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) The... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 55,74 | 0,00 % | ROUNDUP/Aktien New York Schluss: Gewinne - Arbeitsmarktdaten stützen | NEW YORK (dpa-AFX) - Die New Yorker Börsen haben am Dienstag nach einem verhaltenen Start ihre Kursgewinne ausgebaut. Marktbeobachter verwiesen darauf, dass die jüngsten Daten vom US-Arbeitsmarkt trotz... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,430 | 0,00 % | Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? | ||
| BIONTECH | 96,90 | +3,36 % | BioNTech: Ryan Richardson verlässt Vorstand im Herbst | Bei BioNTech steht ein Wechsel im Vorstand bevor. Ryan Richardson wird seine Position als Chief Strategy Officer sowie seine Ämter in Tochtergesellschaften der BioNTech-Gruppe zum 30. September 2025... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 46,430 | 0,00 % | Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? | ||
| ARCUTIS BIOTHERAPEUTICS | 14,910 | +2,47 % | Guggenheim maintains Buy rating on Arcutis Biotherapeutics stock amid prescription growth | ||
| DYNE THERAPEUTICS | 9,380 | +1,85 % | Dyne Therapeutics Prices Public Offering Of About 24.24 Mln Shares At $8.25/shr | WASHINGTON (dpa-AFX) - Dyne Therapeutics Inc. (DYN) announced the pricing of an underwritten public offering of about 24.24 million shares of its common stock at a public offering price of $8.25... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 18,000 | 0,00 % | ARS Pharmaceuticals, Inc.: EURneffy (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) | EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions ALK-Abelló A/S, which owns the rights to... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,110 | 0,00 % | Aktien New York Schluss: Verluste - Sorgen um Krieg in Nahost nehmen zu | NEW YORK (dpa-AFX) - Die sich zuspitzende Lage in Nahost und die Unsicherheit über das weitere Vorgehen der USA haben am Dienstag die US-Börsen belastet. Der New Yorker Leitindex Dow Jones Industrial... ► Artikel lesen |
BIODESIX INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,425 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIODESIX INC finden Sie auf Wallstreet Online.